Bristol-Myers Squibb (BMY) has been active in recent news for various reasons. The company declared common and preferred
dividends of US$0.62 and US$0.50 respectively. In the market, BMY's shares increased by 5%, attracting investor attention. It also released
positive data from the Phase 3 POETYK PsA-1 Trial. The stock was viewed as a top-ranked momentum stock, showing potential for value investors. Despite its highs, BMY stock dropped in parallel to market gains. The company has announced collaborations for Alzheimer's drug development and cancer drug collaboration with BioNTech. In addition, it has
exceeded market returns and reported higher than expected revenue from cancer drug sales. Looming large is a potential patent cliff, which has prompted
Bristol Myers Squibb to plan for $2 billion in cost cuts by 2027. Despite this, the company is viewed as a robust,
high-yield dividend stock with positive long-term growth prospects. BMY recently presented data about promising blood cancer drugs at the EHA Congress. Crucially, BMY's upcoming earnings reports are anticipated with interest. The company invested a staggering $40 billion in the US over five years, and it also bought out 2seventy Bio in a $286M deal reaffirming its intention to continue developing therapies.
Bristol-Myers Squibb BMY News Analytics from Thu, 26 Dec 2024 08:00:00 GMT to Fri, 20 Jun 2025 18:09:41 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
